Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) for its PRESERFLO MicroShunt. This device is designed to reduce intraocular pressure in patients with primary open-angle glaucoma, providing an alternative to conventional surgeries. Glaukos plans to initiate commercial activities for the MicroShunt in late 2021, targeting a full launch by mid-2022, contingent on reimbursement. The company maintains exclusive commercialization rights for the MicroShunt across several key markets, including Australia and the Americas.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 4:40 p.m. CDT. The event will be available via live and archived webcast on their Investors website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent and its successors. The company's advancements aim to transform treatment paradigms in ophthalmology.
Glaukos Corporation (NYSE: GKOS) announced a development and commercialization license agreement with Santen Pharmaceutical for the PRESERFLO™ MicroShunt, replacing prior agreements. Glaukos gains exclusive commercialization rights in the U.S., Australia, Canada, and Latin America, along with full control over development activities. The MicroShunt, aimed at treating glaucoma, has a PMA application pending with the FDA. Santen will continue to manufacture the device. Financial terms of the agreement have not been disclosed.
Glaukos Corporation (GKOS) reported a 23% increase in net sales for Q1 2021, reaching $68.0 million, compared to $55.3 million in Q1 2020. Key segments included $53.7 million from glaucoma and $14.3 million from corneal health. The gross margin was approximately 76%, significantly up from 41% in the prior year. Operating expenses declined by 17% to $63.1 million, leading to a reduced net loss of $16.5 million or ($0.36) per share. The company projects Q2 2021 revenues between $70 million and $72 million.
Summary not available.
Glaukos Corporation (NYSE: GKOS) announced an amended licensing agreement with Intratus, Inc. for the exclusive global license to develop and commercialize Intratus' non-invasive Eyelid Drug Delivery Platform, now including presbyopia treatments. This expands their existing agreement from 2019, which focused on dry eye disease and glaucoma. The platform offers a patient-friendly transdermal approach with promising early human study results. Financial terms were not disclosed, but the partnership aims to enhance Glaukos' portfolio in ophthalmic therapies.
Glaukos Corporation (NYSE: GKOS) will announce its Q1 2021 financial results on Wednesday, May 5, 2021, after market close. A conference call and webcast led by the management team will occur at 1:30 p.m. PDT (4:30 p.m. EDT) on the same day. Glaukos specializes in innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012 with devices like the iStent series. For participation details, please visit investors.glaukos.com.
Glaukos Corporation (NYSE: GKOS) launched two patient-centric initiatives for World Glaucoma Week, aimed at raising awareness of glaucoma. The initiatives include a global education campaign called “Making an iMPACT: Glaucoma Perspectives” featuring interviews with leading physicians and a glaucoma patient. Additionally, Glaukos will collaborate with U.S. eye care institutions to provide free glaucoma screenings. These efforts underline Glaukos' commitment to improving glaucoma treatment and patient education across the globe.
Glaukos Corporation (NYSE: GKOS) announced its management's virtual participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 p.m. EDT. This event will be available via live and archived webcast on Glaukos' Investors website. Glaukos specializes in medical technology and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent series.
Glaukos Corporation (NYSE: GKOS) has appointed Denice Torres and Dr. Leana Wen as new members of its Board of Directors, increasing the board to nine members, eight of whom are independent. The addition aims to enhance the board's expertise as the company continues to expand its global presence in ophthalmic medical technologies. Torres, with over 25 years in healthcare management, previously held leadership roles at Johnson & Johnson, while Dr. Wen is known for her public health advocacy and emergency medicine expertise. Their insights are expected to benefit Glaukos' mission in treating chronic eye diseases.